Vivesto AB (VIVE) AI Stock Analysis

0 Followers

Vivesto AB

(Nasdaq OMX AB:VIVE)

Select Model

Rating:43Neutral

Price Target:SEK 7.00▼(-1.41% Downside)

Action:reiterated

Date:10/08/26

Weak financial performance driven by absent revenue and losses is the dominant factor lowering the score. Oversold technical indicators provide some counterbalance, but poor valuation metrics due to negative earnings limit upside.

Positive Factors

Low leverage and equity cushionA debt-free balance sheet and substantial equity cushion give Vivesto greater financial flexibility than a highly leveraged development-stage biotech. This can support continued research investment and help absorb operating losses, although preserving that cushion depends on improving operations or securing funding.

Negative Factors

Near-zero revenue baseNear-zero reported revenue shows that Vivesto has not yet established a recurring commercial business capable of funding operations. Until a candidate is approved, partnered on meaningful terms, or commercialized, financial performance remains heavily dependent on development progress and available capital.

Vivesto AB (VIVE) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 81.37M
Dividend Yield: ―
Average Volume (3M): 8,673
Price to Earnings (P/E): -8.9
Beta (1Y): 0.56
Revenue Growth: ―
EPS Growth: 32.62%
Country: Sweden
Employees: 4
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Vivesto AB Business Overview & Revenue Model

Company Description

Vivesto AB, established in 1988 and headquartered in Solna, Sweden, specializes in the development, production, commercialization, and sale of pharmaceutical products within human and veterinary oncology, primarily operating in its home country. Its...

How the Company Makes Money

Vivesto AB’s revenue model is primarily that of a development-stage biopharmaceutical company: it seeks to create shareholder value and future earnings by advancing oncology drug candidates through preclinical and clinical development toward regulato...

Vivesto AB Financial Statement Overview

Summary

Zero TTM revenue and persistent net losses of 31.5M with negative cash flows of -24.6M are significant concerns, though offset by a solid balance sheet with positive equity of 158M and low debt.

Income Statement

15Very Negative

Balance Sheet

68Positive

Cash Flow

25Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0	0	0	0	1.01M	26.19M
Gross Profit	-478.00K	0	-3.19M	0	-10.66M	-17.93M
EBITDA	-31.00M	-34.38M	-36.56M	-123.79M	-100.56M	-99.77M
Net Income	-31.54M	-34.08M	-39.75M	-128.74M	-367.03M	-138.94M
Balance Sheet
Total Assets	168.56M	149.04M	172.88M	220.67M	355.88M	594.31M
Cash, Cash Equivalents and Short-Term Investments	23.51M	2.10M	32.29M	77.04M	142.51M	97.27M
Total Debt	0	13.00M	0	0	8.17M	10.43M
Total Liabilities	10.30M	24.46M	14.55M	22.87M	30.45M	44.59M
Stockholders Equity	158.26M	124.58M	158.33M	197.80M	325.42M	549.71M
Cash Flow
Free Cash Flow	-24.64M	-43.81M	-47.25M	-69.40M	-80.79M	-179.91M
Operating Cash Flow	-29.64M	-33.96M	-47.25M	-68.74M	-80.52M	-145.56M
Investing Cash Flow	-18.55M	21.85M	43.40M	63.73M	-45.28M	118.65M
Financing Cash Flow	48.94M	13.00M	0	0	128.76M	-5.81M

Vivesto AB Technical Analysis

Technical Analysis SentimentNegative

Last Price7.10

Price Trends

50DMA8.03Negative

100DMA8.38Negative

200DMA8.57Negative

Market Momentum

MACD-0.18Negative

RSI40.67Neutral

STOCH23.90Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:VIVE, the sentiment is Negative. The current price of 7.10 is below the 20-day moving average (MA) of 7.31, below the 50-day MA of 8.03, and below the 200-day MA of 8.57, indicating a bearish trend. The MACD of -0.18 indicates Negative momentum. The RSI at 40.67 is Neutral, neither overbought nor oversold. The STOCH value of 23.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:VIVE.

Vivesto AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SE:VIVE against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:NANEXA	52Neutral	SEK 1.87B	13.09	87.15%	―	2370.13%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:NICA	46Neutral	SEK 53.75M	0.48	23.67%	―	163.58%	―
SE:SPAGO	43Neutral	SEK 34.97M	-1.17	-87.37%	―	-97.52%	31.31%
SE:VIVE	43Neutral	SEK 81.37M	-8.91	-21.64%	―	―	32.62%
SE:CLS.B	41Neutral	SEK 85.68M	-1.33	-66.41%	―	-47.42%	44.01%
SE:SPEC	38Underperform	SEK 22.68M	-0.12	-57.15%	―	―	16.02%

* Healthcare Sector Average

Performance Comparison

SE:VIVE and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:VIVE	Vivesto AB	7.10	-12.61	-63.98%
SE:CLS.B	Clinical Laserthermia Systems AB Class B	1.79	-6.47	-78.29%
SE:SPEC	SpectraCure AB	0.01	-0.12	-89.05%
SE:NICA	Nanologica AB	0.17	-0.99	-85.53%
SE:SPAGO	Spago Nanomedical AB	0.05	-0.07	-58.93%
SE:NANEXA	Nanexa AB	10.00	8.31	491.72%

Vivesto AB Corporate Events

Vivesto’s Paccal Vet Data Spotlighted at Key Veterinary Oncology Conference

Sep 24, 2026

Vivesto AB announced that topline data from its Paccal Vet clinical studies in dogs and cats are being presented in two posters at the Veterinary Cancer Society Annual Conference 2026 in Minneapolis, reinforcing the company’s growing presence in vete...

Vivesto’s Paccal Vet Shows Promising Efficacy and Safety in Feline Cancer Study

Sep 17, 2026

Vivesto AB has reported positive topline results from its dose-finding study of Paccal Vet in cats with solid tumors, showing clear indications of anti-tumor activity across multiple tumor types. The trial enrolled 21 cats and identified biological r...

Vivesto’s Paccal Vet Shows Survival Benefit in Canine Hemangiosarcoma Study

Sep 15, 2026

Vivesto AB has reported positive topline results from an open-label pilot study of its veterinary cancer drug candidate Paccal Vet in dogs with Stage I-II splenic hemangiosarcoma following splenectomy. The median overall survival of 135 days exceeded...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 08, 2026

Vivesto AB AI Stock Analysis